Full Text View
Tabular View
No Study Results Posted
Related Studies
Safety Study of Injections of Autologous/Allogeneic TGFbeta-resistant LMP2A-specific Cytotoxic T-lymphocytes (CTL) (TGF-beta)
This study is currently recruiting participants.
Verified August 2012 by Baylor College of Medicine
Study NCT00368082   Information provided by Baylor College of Medicine

First Received on August 22, 2006.   Last Updated on August 29, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Lymphoma
Hodgkin's Disease
Relapse
Lymphoma, Non-Hodgkin
Additional conditions recognized in this trial
Hodgkin Disease
More general conditions related to this trial
Immune System Diseases
Immunoproliferative Disorders
Lymphatic Diseases
Lymphoproliferative Disorders
Neoplasms
Neoplasms by Histologic Type
Sponsors listed in this trial
Baylor College of Medicine
Texas Children's Hospital
The Methodist Hospital System
Center for Cell and Gene Therapy, Baylor College of Medicine


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services